Plain-English translation of NCT06260410 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study that follows patients receiving Lu-PSMA, a targeted radioactive therapy designed to treat advanced prostate cancer. Researchers will collect blood samples and track how well the treatment works and how safe it is. The goal is to better understand which patients benefit most from this medication and to gather safety information from everyday clinical use.
While this medication shows promise in treating advanced prostate cancer, doctors need more information about how it performs in real patients and which blood markers can predict who will respond best. This study fills that gap by collecting data from actual treatment.
You likely qualify if…
You likely don't qualify if…
As a participant, you would continue your regular treatment appointments at Erasmus Medical Center while the research team collects blood samples and gathers information about how your cancer is responding. There are no extra procedures beyond what's already part of your standard care — the study simply involves sharing your medical data and providing blood samples so researchers can track your progress and better understand how well the treatment is working.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Netherlands
Enrollment target
~150 participants
Started
February 2024
Primary completion
February 2027
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Stijn Koolen, PhD
Erasmus Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.